AMRX · Amneal Pharmaceuticals, Inc. · Investor Relations

Company Contact: Amneal Pharmaceutical LLC 833-582-0812 FOR IMMEDIATE RELEASE – 03/24/2026 – Bridgewater, New Jersey, Amneal Pharmaceuticals LLC is voluntarily recalling one lot of Magnesium Sulfate in Water for Injection, USP, 4g/100mL, IV bag, to the hospital level. A Magnesium Sulfate in Water for Injection pouch was found to contain an IV bag of Tranexamic Acid in 0.7% Sodium Chloride Injection, 10 mg/mL. Risk Statement: There is a reasonable probability that delay in receiving magnesium therapy could result in life-threatening or long-term morbidity in pregnant individuals with preeclampsia or eclampsia due to the potential to develop seizures. Additionally, delay in receiving magnesium therapy in preterm pregnant individuals could result in long-term morbidity for the preterm neonate due to complications of prematurity. Amneal has not received any adverse event reports related to this recall. If Tranexamic Acid (TXA) is inadvertently administered it could

BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following upcoming investor conference: Barclays 28 th Annual Global Healthcare Conference Date: March 10, 2026 Fireside Chat: Tuesday, March 10, 2026, at 11:00AM EST Location: Miami, FL A webcast of the presentation will be available on Amneal’s Investor Relations website at https://investors.amneal.com . A replay of the webcast will be available following the event. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million , Adjusted EBITDA of $175 million ; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion ; GAAP Net Income of $72 million ; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million ; Adjusted EBITDA of $688 million ; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2025. “We are extremely pleased with

BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disciplined criteria for market capitalization, liquidity, sector representation, and sustained profitability. Amneal’s inclusion reflects the Company’s consistent operating and financial performance and places it among a select group of pharmaceutical and biotechnology companies that meet the index’s screening requirements. “We are pleased to be included in the S&P SmallCap 600 Index, which reflects the progress we have made executing our strategy